about
Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cellsTumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccinesToward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challengesModulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancerBrain metastases from breast cancer: lessons from experimental magnetic resonance imaging studies and clinical implications.Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycinOlive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo.Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells.Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in miceTrastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model.Effectiveness of trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting: a controlled cohort study.IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.Trastuzumab for small HER-2+ breast cancer: small tumor, big decisionTreatment of HER2-positive metastatic breast cancer following initial progression.Resistance to Trastuzumab in Breast Cancer.The Role of Adaptive Immunity in the Efficacy of Targeted Cancer TherapiesA novel fully human antitumor immunoRNase resistant to the RNase inhibitorIsolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice.TP53 status determines clinical significance of ERBB2 expression in ovarian cancer.Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis BNon-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies.The tumor microenvironment: the making of a paradigm.Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDCEffects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.Integrating conventional and antibody-based targeted anticancer treatment into immunotherapySmall molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer.Heart failure and chemotherapeutic agents.Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance.Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells.Physicochemical and biological characterization of a biosimilar trastuzumab.Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer.Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer.Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells.Glycoengineering of antibody (Herceptin) through yeast expression and in vitro enzymatic glycosylation.ScFvs as Allosteric Inhibitors of VEGFR-2: Novel Tools to Harness VEGF Signaling.
P2860
Q24561962-4A9E1304-FBBB-4982-B4DE-73256F26E13DQ24804837-33034433-4B8F-4DB3-BC6B-64427160734CQ26995399-5387A626-7C20-4A86-ABED-AF9E172E1336Q28729012-2C927CAD-DB3E-43CB-9B32-553B98068E6CQ30708273-C0C14E45-CBDC-403C-83B9-C40C653CEE64Q30839490-27872507-CE23-4794-AFD7-21CB5CD4D26FQ33284158-374452CB-E2C1-4C36-9760-BC4D7584A533Q33385649-79A54AC5-DD27-44B4-8678-8AFF3A8EEC6FQ33410392-1898E825-0165-4115-A2F6-331DBB41F779Q33658544-8ECF9EB5-41EA-4667-A78E-BF2243A641FCQ33743601-318FE56E-6B42-4F46-9FBD-8B575902FA17Q33823499-4637D651-7AF7-4FDE-891F-4B9018E81165Q34000333-51AC603E-DFC8-4955-96C9-66853E6B5B9EQ34641036-F1024F9C-5DA4-466B-8DCD-B13E2FBCE4F4Q34798580-B8CEBCB4-4FCE-4CA0-AE82-BCFA7C456631Q35913229-C759A995-FB1B-4DE5-8547-B210B2D22427Q36275971-81E3FF2C-AFBB-4450-A24F-10D313E9E2A4Q36318226-DB68EB20-BABA-44DC-B195-88F889EC2F9CQ36535465-4AFEA706-03A5-4A23-8553-9D082AFBBD83Q36610794-C9CFA14C-0718-4959-A3A6-7EEB48FC7BBFQ36694110-0A07F1E2-8572-4244-BFB3-F2DD2FF922D8Q36695189-381188DC-7959-481E-93B6-E0E891EE8368Q37187980-31B7BC3C-4D9B-45D8-9BBC-3A73B8B5468DQ37323537-F7FBC94A-31C8-4C87-8C2E-F9FC9EDD6810Q37373366-DE3B15A7-D095-46F8-96F3-F99259DE4D80Q37403194-10F4DEB6-D75D-4656-AAAA-26663DD11C6AQ37586081-862C2493-D3A8-47D2-8A9C-CEB9A4D5C6A5Q37592814-8A4C7AFA-6E42-4118-B09B-33795E15BBBDQ38253835-5AD788CC-E090-4F63-A0C6-1DAA7F4DD25DQ38559133-A35F8472-7C79-48BB-9E27-8BA99447B374Q38619194-7D49DF81-2BD6-4F96-96E9-72E3772AD55EQ39355884-25EFE558-47AC-418B-BB31-129675BC97A2Q39559611-1A6A2F12-4EFB-4359-B4A0-2C1FF426AD57Q39943622-5E922E17-E3D6-4FA7-9185-5810FD8C62CDQ41443472-BC75B9FA-025B-4C35-851D-F095FC9E3349Q44068928-D65F8216-78D0-4A56-A061-2B1DA8988006Q46228471-3394FA6E-8452-4469-A859-990732F85B8BQ50042227-070D2F91-4495-4EB2-A2AC-961111A7F697Q50133462-9D81F6F7-7BEF-4EF2-B113-173C388CB430Q54112592-1338272D-F96A-419D-8759-22B79C42C6BD
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Mechanism of action of anti-HER2 monoclonal antibodies.
@ast
Mechanism of action of anti-HER2 monoclonal antibodies.
@en
Mechanism of action of anti-HER2 monoclonal antibodies.
@nl
type
label
Mechanism of action of anti-HER2 monoclonal antibodies.
@ast
Mechanism of action of anti-HER2 monoclonal antibodies.
@en
Mechanism of action of anti-HER2 monoclonal antibodies.
@nl
prefLabel
Mechanism of action of anti-HER2 monoclonal antibodies.
@ast
Mechanism of action of anti-HER2 monoclonal antibodies.
@en
Mechanism of action of anti-HER2 monoclonal antibodies.
@nl
P356
P1433
P1476
Mechanism of action of anti-HER2 monoclonal antibodies.
@en
P2093
J Albanell
P304
P356
10.1093/ANNONC/12.SUPPL_1.S35
P478
12 Suppl 1
P50
P577
2001-01-01T00:00:00Z